Revenue - Revenue from Licensing Arrangements (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Mar. 31, 2020	Jun. 30, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Collaborative Arrangements and Co-Promote Agreement
Milestone payment			$ 13,194	$ 18,257	$ 40,365	$ 53,127
Viatris
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable		$ 18,500
Milestone payment	$ 1,500
Viatris | Sales milestones
Collaborative Arrangements and Co-Promote Agreement
Milestone payment		37,500			205,000
Viatris | Revefenacin Monotherapy (TD-4208)
Collaborative Arrangements and Co-Promote Agreement
Milestone payment					160,000
Viatris | YUPELRI Monotherapy
Collaborative Arrangements and Co-Promote Agreement
Milestone payment		9,000
Viatris | YUPELRI Monotherapy | Sales milestones
Collaborative Arrangements and Co-Promote Agreement
Milestone payment					150,000
Viatris | Future potential combination products
Collaborative Arrangements and Co-Promote Agreement
Milestone payment		7,500			$ 45,000
Viatris | Future potential combination products | Development and Sales Milestones
Collaborative Arrangements and Co-Promote Agreement
Milestone payment		$ 54,000